Drug Trial Radar · NCT05934526
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Last checked: Nov 20, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
390
Actual
Start
Dec 28, 2023
Primary completion
Nov 27, 2025
Study completion Dec 22, 2025
Sponsor
- Lead sponsor
- GB002, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Conditions
- Pulmonary Arterial Hypertension
Interventions
PlaceboDrug
Matching capsule containing placebo
SeralutinibDrug
Capsule containing seralutinib
Generic Dry Powder InhalerDevice
Generic dry powder inhaler for seralutinib or placebo delivery
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in distance achieved on the six-minute walk test (6MWT), six-minute walk distance (Δ6MWD) from baseline to Week 24Time frame: Baseline to 24 weeks
Locations
166 sites in 31 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Valley Advanced Lung Diseases Institute
Fresno, California
Keck Medical Center of USC
Los Angeles, California
Dept of Veterans Affairs Greater Los Angeles Healthcare System
Los Angeles, California
University of California, Irvine Medical Center
Orange, California
UC Davis Health
Sacramento, California
Stanford Healthcare
Stanford, California
Winchester Center for Lung Disease
New Haven, Connecticut
The George Washington University Medical Faculty Associates
Washington D.C., District of Columbia
University of Florida Clinical Research Center
Gainesville, Florida
Mayo Clinic
Jacksonville, Florida
Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead
Atlanta, Georgia
Emory University
Atlanta, Georgia
Northside Hospital Laboratory - Atlanta
Atlanta, Georgia
UI Health Hospital
Chicago, Illinois
University of Iowa Hospitals & Clinics
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Norton Hospital
Louisville, Kentucky
Tufts Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
M Health Fairview University of Minnesota Medical Center - East Bank
Minneapolis, Minnesota
University of Missouri
Columbia, Missouri
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
University of New Mexico Health Sciences Center
Albuquerque, New Mexico
NYU Langone Health
New York, New York
University of Rochester Medical Center
Rochester, New York
UNC Hospitals
Chapel Hill, North Carolina
Duke University Medical Center - Duke South
Durham, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
INTEGRIS Cardiovascular Physicians, LLC
Oklahoma City, Oklahoma
Oregon Health & Science University
Portland, Oregon
The Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Temple Heart and Vascular Institute (Outpatient Clinic)
Philadelphia, Pennsylvania
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Medical University of South Carolina - Nexus Research Center
Charleston, South Carolina
UT Southwestern Medical Center
Dallas, Texas
Showing 40 of 166 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.